《JPM 2023 Sutro.pdf》由会员分享,可在线阅读,更多相关《JPM 2023 Sutro.pdf(25页珍藏版)》请在三个皮匠报告上搜索。
1、NON-CONFIDENTIALNON-CONFIDENTIAL40thAnnual J.P.MorganHealthcare ConferenceJanuary 2022Sutro Biopharma NASDAQ:STRONON-CONFIDENTIALForward Looking StatementsThis presentation and the accompanying oral presentation contain“forward-looking”statements that are based on our managements beliefs and assumpt
2、ions and on information currently available to management.Forward-looking statements include all statements other than statements of historical fact contained in this presentation,including information concerning our future financial performance,business plans and objectives,current and future clini
3、cal activities,timing and success of our ongoing and planned clinical trials and related data,updates and results of our clinical trials and related data,timing and success of our planned development activities,our ability to obtain and maintain regulatory approval,the potential therapeutic benefits
4、 and economic value of our product candidates,potential growth opportunities,financing plans,potential future milestone and royalty payments,competitive position,industry environment and potential market opportunities for the Companys product candidates.Forward-looking statements are subject to know
5、n and unknown risks,uncertainties,assumptions and other factors,including risks and uncertainties related to our cash forecasts,our and our collaborators ability to advance our product candidates,the receipt and timing of potential regulatory submissions,designations,approvals and commercialization
6、of product candidates,the timing and results of preclinical and clinical trials,and the expected impact of the COVID-19 pandemic on our operations.It is not possible for our management to predict all risks,nor can we assess the impact of all factors on our business or the extent to which any factor,
7、or combination of factors,may cause actual results to differ materially from those contained in any forward-looking statements we may make.These factors,together with those that may be described in greater detail under the heading“Risk Factors”contained in our most recent Annual Report on Form 10-K,
8、Quarterly Report on Form 10-Q and other reports the company files from time to time with the Securities and Exchange Commission,may cause our actual results,performance or achievements to differ materially and adversely from those anticipated or implied by our forward-looking statements.You should n
9、ot rely upon forward-looking statements as predictions of future events.Although our management believes that the expectations reflected in our forward-looking statements are reasonable,we cannot guarantee that the future results,levels of activity,performance or events and circumstances described i
10、n the forward-looking statements will be achieved or occur.Moreover,neither we nor our management assume responsibility for the accuracy and completeness of the forward-looking statements.We undertake no obligation to publicly update any forward-looking statements for any reason after the date of th
11、is presentation to conform these statements to actual results or to changes in our expectations,except as required by law.This presentation also contains estimates and other statistical data made by independent parties and by us relating to marketsize and growth and other data about our industry.Thi
12、s data involves a number of assumptions and limitations,and you are cautioned not to give undue weight to such estimates.In addition,projections,assumptions,and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree
13、of uncertainty and risk.2NON-CONFIDENTIALDrug Discovery Platform Enables the Potential for Best-in-Class MoleculesPrecise novel design to enhance efficacy and safety across multiple modalities and targetsEnhanced tumor targeting of cytotoxic payloadsBispecificADCISAC:Immune-stimulatingADC:targeting
14、novel payloadsBispecificAntibodyTumor or Stromal AntigenImmune Cell EngagerOptimized format and affinityImproved specificity for optimized therapeutic windowTumor AntigenDual Tumor AntigensConjugatedAntibodyADC or ISACiADCTumor AntigenSite-specific dual drug conjugate with complementarymodalities(TM
15、E modulator+/-immune modulator)Immune Cell EngagerModalityDrug PropertiesTargetStructureCytokine DerivativeProdrug cytokine targeting functional cytokine to tumorProdrug Cytokine DerivativeTumor Selective MaskReleasable maskcytokine3NON-CONFIDENTIALRobust Pipeline through Wholly-Owned and Partnered
16、ProgramsFour product candidates advancing in the clinic and late-stage discovery programsModalityProgramTargetIndicationDiscoveryPreclinicalPhase 1/1bPhase 2/3PartnerAntibody-Drug ConjugateSTRO-002FolR ADCOvarian CancerOvarian Cancer(bevacizumab combo)Endometrial CancerNSCLC/Non-Gyn CancersSTRO-001C
17、D74 ADCLymphomasMultiple MyelomaCC-99712BCMA ADCMultiple MyelomaMultiple Myeloma(GSI combo)DiscoveryROR1,Tissue Factor Solid TumorsBispecific ADC M1231MUC1-EGFR ADCNSCLC&Esophageal Cancer(1)T-Cell Engager Preclinical5T4-CD3 TCESolid TumorsCytokine DerivativeNot DisclosedCytokine targetCancerDiscover
18、yIFN,IL-12,IL-18Solid TumorsVaccineVAX-2424-valent pneumococcalInvasive Pneumococcal Diseaseconjugate vaccine(1)EMD Serono is the biopharmaceutical business of Merck KGaA,Darmstadt Germany in the US(2)Cytokine Derivative program with Merck includes two molecules derived from one undisclosed targetFa
19、st Track DesignationOrphan Drug DesignationOrphan Drug Designation(2)2 Molecules(Greater China)(Greater China)4IND clearanceNON-CONFIDENTIALAchievements and MilestonesClinical data readouts and partnerships provide multiple 2022 value drivers for Sutro STRO-002,FolR ADCGreater China deal with Tasly(
20、Dec.2021)Ovarian cancer dose-expansion interim data (Jan.2022)Dose-expansion data with durability at a scientific meeting(2H 2022)EOP1/2 meeting(1H 2022)Initiate pivotal trial in ovarian cancer(YE 2022)First patient dosed in endometrial cancer(Nov.2021)First patient dosed in bevacizumab combination
21、trial(1Q 2022)Support Tasly for initiation of clinical development activities in Greater China(2022)Initiate clinical trial for NSCLC and other non-gynecologic solid tumors(2H 2022)STRO-001,CD74 ADC Greater China deal with BioNova(Oct.2021)Support BioNova for initiation of clinical development activ
22、ities in Greater China(2022)Determine RP2D through dose escalation(2022)Cell-Free Manufacturing for Partnered Programs Provide manufacturing materials&support for CC-99712,BCMA ADC in clinical development(BMS)Manufacture initial product for potential clinical development of cytokine derivative(Merck
23、)Manufacture M1231 product,MUC1-EGFR ADC in clinical development(EMD Serono)Supply cell-free extract&reagents to Vaxcyte for VAX-24,IND clearance announcedSupport tech transfers and enable BMS and EMD Serono to manufacture from Sutros cell-free extract 5NON-CONFIDENTIALNON-CONFIDENTIALFolR-Targeting
24、ADCPotential Best-in-Class ADC forOvarian CancerSTRO002NON-CONFIDENTIALSTRO 002Highly optimized ADC designed to drive efficient tumor responses across a broad range of target antigen levels1Sutro-proprietary tubulin-targeting 3-aminophenol hemiasterlin warhead,SC2092Based on STRO-002 pre-clinical mo
25、dels showing immune stimulation at site of tumor upon cell deathSTRO-002 is a homogeneous antibody drug conjugate(ADC)with a drug-antibody ratio(DAR)of 4,targetingfolate-receptor alpha(FolR)12343Protease-cleavable linker42pAMFFolR1Hemiasterlin-derivative warheadY180F404FolR is overexpressed in certa
26、in cancers including ovarian cancer and endometrial cancerPrecisely positioned non-natural amino acids,p-azidomethyl-L-phenylalanine(pAMF),at positions Y180 and F404 on the heavy chainStable protease-cleavable linkers,with rapid clearance of toxic catabolite after release and cell killingWarhead is
27、hemiasterlin-derivative1with potentially dual mechanism against the tumor tubulin-inhibitor cytotoxin,less sensitive to P-gp transport and induces immunogenic response upon cell death27NON-CONFIDENTIALSTRO 002Phase 1 Study in Patients with Advanced Ovarian CancerTwo-part design to explore safety,ant
28、i-tumor activity,dosing,and FolR enrichment strategyProtocolBaselineCharacteristicsInclusive of all FolR expression levels;tissue samples voluntary and samples received from 25%N=25TPS 25%N=8Total Patients Enrolled N=44Not dosed by Nov.8N=1Randomized Dose LevelsTotal N=43Ovarian CancerPatients4.3 mg
29、/kg N=235.2 mg/kg N=20Median age,years(range)63(3991)56(4072)60(3991)Median time since diagnosis,years(range)1.8(0.94.4)2.9(0.75.1)2.8(0.75.1)Number of prior lines of therapyMedian3.02.02.0Mean(St.Dev.)2.5(0.95)2.5(1.05)2.5(0.98)Previous Therapies,n(%)bevacizumab13(57%)14(70%)27(63%)PARP Inhibitor15
30、(65%)13(65%)28(65%)Patient Status as of November 8,2021Patient Baseline Characteristics 9NON-CONFIDENTIAL20%-30%2 pts had 0%Maximum Changein Tumor Target Lesions(N=33)Partial Response4.3 mg/kg5.2 mg/kgTreatment ongoingas of Nov 8,2021PR confirmed by next scheduled scan(after Nov.8,2021)Dose Expansio
31、nSTRO 002Dose Response DemonstratedInterim data suggest that 5.2 mg/kg starting dose leads to higher response ratesPRu*PRu PRu*PRPRPRPRPRu*PRu*PRPRPRStarting Dose,Q3WNote:Data as of Nov.8,2021.5 PRu were of interest and followed up subsequent to the data cutoff date.4 PR confirmed at their next sche
32、duled scan and 1 was SD.*10NON-CONFIDENTIALStarting DoseBest Overall Response(BOR)4.3 mg/kg5.2 mg/kgAll ComersEvaluable patients N=16N=17N=33PR347PR confirmed by next scheduled scan post Nov.8,2021044Total PR3811ORR(%)18.8%47.1%33.3%SD 10 4 14PD3 5 8 Dose ExpansionSTRO 002Objective Response by RECIS
33、T v1.133%ORR rate in all 33 evaluable patients,unenriched for FolR expression47.1%ORR in patients starting at the 5.2 mg/kg dose level 33.3%ORR in all patients Interim data suggest that 5.2 mg/kg starting dose leads to higher response ratesAll 4 patients with PRu treated at 5.2 mg/kg were subsequent
34、ly confirmed at the next scheduled scanNote:Data as of Nov.8,2021.5 PRu were of interest and followed up subsequent to the data cutoff date.4 PR confirmed at their next scheduled scan and 1 was SD.11NON-CONFIDENTIALDose ExpansionSTRO 002Robust Anti-tumor Activity and Disease Control Demonstrated Res
35、ponders experienced rapid tumor reduction or a steady deepening of responseChange from baseline(%)Weeks since first treatment20-30-1000Change in Sum of Diameters for Target Lesions Over Time(N=33)04823640Starting Dose,Q3W4.3 mg/kg5.2 mg/kgTreatment ongoingas of Nov 8,2021Note:Data as of N
36、ov.8,2021.12NON-CONFIDENTIALEncouraging Response Rates and Preliminary Data on DurabilityInterim data suggest initiating with 5.2 mg/kg followed by a dose adjustmentTreatment Duration on Patients with at Least One Dose(N=43)Dose ExpansionSTRO 002Initial data show partial responses confirmed&maintain
37、ed following dose adjustmentMedian Duration of Response has not been reached and 23 of 43 patients remained on study at Nov.8,2021Data to inform RP2D with final decision pending more data maturity+048236Weeks since first treatmentIndividual patients treated with STRO-002Dose Level,Q3W3.5
38、mg/kg4.3 mg/kg5.2 mg/kg+Treatment ongoing as of Nov 8,2021(N=23)Dose adjustmentPRNo post-baseline scan as of data cut-off+Note:Data as of Nov.8,2021.44thpatient had not been dosed by this date.+13NON-CONFIDENTIALPlatinum-Resistant Ovarian Cancer Patient Treated at 4.3 mg/kg Dose LevelOngoing Partial
39、 Response with 72%reduction in tumor burdenDose ExpansionSTRO 002Initial diagnosis:Stage IV ovarian cancer,Jan 20203 Prior Regimens:Resistant to 1st Neoadjuvant/adjuvant Carbo/Taxol/Taxotere Refractory to 2ndand 3rd with progressive disease Liposomal doxorubicin Gemcitabine Lateral Abdominal Wall Ax
40、illary Lymph NodeInter-aortocaval LNExternal Iliac LNBaseline Screening of Target Lesions May 17,2021Scans at Cycle 5 Target Lesions September 8,2021Lateral Abdominal Wall Axillary Lymph NodeInter-aortocaval LNExternal Iliac LN14NON-CONFIDENTIALPatients at the 5.2 mg/kg starting doseand TPS 25%demon
41、strated 53.8%ORR(n=13)ORR by TPS Expression Levels(Total Samples N=33)Dose ExpansionSTRO 002TPSOverallTPS 25%TPS 25%TPS 50%TPS 75%ORR33.3%12.5%40.0%42.1%43.8%Number of patient samplesN=33N=8N=25N=19N=16PR(1)1111087 Potential Market Size(%)100%30%70%(1)PR classification includes the 4 of 5 patients w
42、ho were confirmed by their next scheduled scan after Nov.8,2021.Note:Data as of Nov.8,2021.TPS Identified as Scoring Algorithm Appropriate for STRO-002Exploratory analysis suggests TPS 25%correlated with higher response Tumor Proportion Score(TPS)Percent of tumor cells showing staining of any intens
43、ity Does not require analysis of intensity levels and easy to score Commonly used in clinical practice Established reproducibility across different biomarkers(e.g.,PD-L1)15NON-CONFIDENTIALEmerging Safety Profile is Manageable 85.5%of TEAEs were Grade 1-2No new safety signals were observed,including
44、the absence of keratopathy4.3 mg/Kg(N=23)5.2 mg/Kg(N=20)Total(N=43)Grade 3n(%)Grade 4n(%)Grade 5n(%)Grade 3n(%)Grade 4n(%)Grade 5n(%)Grade 3n(%)Grade 4n(%)Grade 5n(%)Subjects reporting at least 1 event13(57)4(17)08(40)8(40)1(5)21(48)12(28)1(2)Neutropenia(1)10(44)4(17)06(30)8(40)1(5)16(37)12(28)1(2)F
45、ebrile Neutropenia1(2)00001(5)1(2)01(2)White blood cell count decreased4(17)1(4)01(5)2(10)05(12)3(7)0Anemia1(4)003(15)004(9)00Arthralgia4(17)000004(9)00Diarrhea2(9)0001(5)02(5)1(2)0Platelet count decreased2(9)001(5)003(7)00Thrombocytopenia0002(10)002(8)00Vomiting0002(10)002(8)00Fatigue2(9)000002(8)0
46、0Activated partial thromboplastin time prolonged2(9)000002(8)00Hyponatremia2(9)000002(8)00Neuralgia2(9)000002(8)00Acute kidney injury0002(10)002(8)00(1)Neutropenia included the following preferred terms:neutropenia,febrile neutropenia,and neutrophil count decreased.Note:Data as of Nov.8,2021.Dose Ex
47、pansionSTRO 002Asymptomatic neutropenia was the leading TEAE,resulting in treatment delay or dose reductionNeutropenia resolved with 1 week delay G-CSF,in the majority of casesFebrile neutropenia is rareOne Grade 5 event at the 5.2 mg/kg dose cohort One Grade 3 event at the 4.3 mg/kg dose cohort Pro
48、tocol was updated to require dose reduction for Grade 4 neutropeniaDose reductions ameliorated neutropeniaMost Common G3+TEAEs(2 Subjects)by Dose16NON-CONFIDENTIALPatients at the 5.2 mg/kg starting dose and TPS 25%demonstrated 53.8%ORR(7/13)Dose ExpansionSTRO 002Dose Expansion Interim Data Provide I
49、nitial Insights on Go-Forward StrategyEmerging data inform potential starting dose and enrichment strategyTotal of 11 confirmed PR(1)out of 33 RECIST v1.1 evaluable patients 33%ORR,across all FolR expression levels and both dose levels47%ORR(8/17)in unenriched patients starting at the 5.2 mg/kg dose
50、 level Initial data suggest responses at 5.2 mg/kg are maintained,even when subsequent dose reductions are implementedInterim data suggest TPS 25%are correlated with higher response rate,with 40%ORR(10/25)observed in both dose levelsBased on our patient observations,we believe STRO-002 may be an app
51、ropriate therapy for 70%of these patientsNo new safety signals were observed,including the absence of keratopathy85.5%of TEAEs were Grade 1-2Neutropenia was the leading TEAE,resulting in treatment delay or dose reductionProtocol was updated to require dose reduction for Grade 4 neutropeniaOverall Ef
52、ficacy Dose Response Biomarker Safety(1)PR classification includes the 4 of 5 patients who were confirmed by their next scheduled scan after Nov.8,2021 and percentages on slide include such subsequently confirmed PRs as appropriate.Note:Data as of Nov.8,2021.17NON-CONFIDENTIALDose-escalation cohort3
53、9 patients,enrollment completed August 2020Dose-expansion cohort44 patients enrolled in US and Spain sites,enrollment completed November 2021Combo study with bevacizumabTrial is open and enrolling patientsFPI planned for early 2022Registration-directed trialPending FDA EOP1 meetingPrecedent from sin
54、gle-arm registration-directed trial in advanced ovarian cancerOvarian CancerOther Solid TumorsEndometrial cancer cohortInitial enrollment planned for 15 patientsFPI December 2021Cohort is open and enrolling patientsNSCLC and Other TumorsPotential for a basket study design with other FolR expressing
55、cancersNonclinical work ongoingSTRO 002Progressing&Expanding the STRO-002 Franchise Additional clinical studies in ovarian&endometrial,and nonclinical work on other tumor types18NON-CONFIDENTIALNON-CONFIDENTIALCD74-TargetingADCPotential First and Best-in-Class ADC for B-Cell MalignanciesSTRO001NON-C
56、ONFIDENTIAL1STRO-001 is a homogeneous antibody drug conjugate(ADC)with a drug-antibody ratio(DAR)of 2,targeting CD74:Comprises two non-cleavable linker-warheads that are stable in circulationCD74F404pAMF23Non-cleavablelinkerCD74 is expressed in many hematological cancers and rapidly internalizedThe
57、active catabolite,Maytansinoid derivative,efficiently kills tumor cells following internalization of the ADC and was designed to minimize bystander effectsMaytansinoidwarhead412 Conjugation through precisely positioned non-natural amino acids.p-azidomethyl-L-phenylalanine,at positions F404 on the he
58、avy chain43STRO 001Potential First-in-Class Molecule for Patients with NHL and MMStable CD74 targeting ADC for hematological cancers designed to minimize bystander effectsSTRO 00120NON-CONFIDENTIALR/R multiple myeloma(N=30)R/R NHL(N=30)CohortACohort BRP2DRP2DSTRO-001-BCM1 Dose Escalation StudyNHL Co
59、hort Update atASH 2020A total of 21 patients have been treated with STRO-001 and 18 patients were evaluable for response as of October 30,2020Dose range 0.05-2.5 mg/kg and MTD has not been reached1 DLT of grade 3 pulmonary embolism was observed(1)Following previously announced protocol amendment req
60、uiring pre-screening for patients at risk for thromboses,no additional thromboembolic events have been observedDosing frequency was modified from Q2W(28-day cycle)to Q3W(21-day cycle)for doses 0.91 mg/kg0.91 mg/kg1.27 mg/kg1.78 mg/kg2.5 mg/kg3.5 mg/kgMTDX mg/kg0.0750.65 mg/kgSingle-dose cohortsN=6 t
61、otal NonePatients treatedDLTsN=6 1 DLTN=3NoneN=3NoneN=3None(1)DLT disclosed in 2019,patient with bulky lymphadenopathy and concurrent DVT receiving 0.91 mg/kg Q3WNote:Data as of October 30,2020 from data reported at ASH 2020.As of October 2021,the last reported doses levels were of 5.0 mg/kg in the
62、multiple myeloma(MM)cohort and 4.2 mg/kg in the non-Hodgkins lymphoma(NHL)cohort.Cohort B,NHL Dosing Schedule(ASH 2020)STRO 001STRO-001-BCM1 Study Design and UpdatesOngoing Phase 1 dose escalation study with NHL update at ASH 2020STRO 00121Dose escalation ongoing at 4.2 mg/kg for NHL&5.0 mg/kg for M
63、M NON-CONFIDENTIALBaseline Characteristic(N=21)Age,median(range),years64.5(2182)Time from diagnosis,median(range),years6.0(1.029.8)NHL subtype,n(%)21(100)DLBCL7(33)Follicular lymphoma7(33)MCL2(10)Marginal zone lymphoma2(10)Burkitts Lymphoma1(5)Composite DLBCL/FL1(5)Composite DLBCL/CLL1(5)Number of p
64、rior therapies,median(range)5(1-12)Prior therapies,n(%)Autologous stem cell transplant2(10)Unrelated allogeneic stem cell transplant1(5)CAR-T therapy3(14)TEAEs by Grade,Patients With 1 Event,n(%)Occurring in 15%Grade 1Grade 2Grade 3Grade 4Nausea5(23.8)4(19.0)00Fatigue4(19.0)3(14.3)00Chills7(33.3)000
65、Anemia3(14.3)2(9.5)1(4.8)0Headache2(9.5)4(19.0)00Dyspnea1(4.8)3(14.3)1(4.8)0Abdominal pain4(19.0)1(4.8)00Infusion related reaction1(4.8)3(14.3)00Vomiting2(9.5)2(9.5)00Decreased appetite3(14.3)1(4.8)00Pyrexia3(14.3)1(4.8)00Note:Data as of October 30,2020 from ASH 2020.ASH 2020 Update in NHL CohortHea
66、vily pre-treated patient population with 5 median lines of prior therapiesSTRO 00122NON-CONFIDENTIALResponses to STRO-001Treatment DurationBest ResponsePatients,nSTRO-001 DoseNHL subtypeCR10.075 mg/kgDLBCLPR20.65,1.27 mg/kgDLBCLSD31.27,1.78,2.5 mg/kgMarginal Zone and FollicularPD12MultipleEncouragin
67、g Interim Treatment Duration and ResponsesPartial responses in two DLBCL patients who had progressed on CAR-T(1)18 patients are evaluable for response as of October 30,2020 Note:Data as of October 30,2020 from ASH 2020.DoseDemographics and Level,Diagnosismg/kgPrior TherapiesBest ResponsesDoses Recei
68、vedDuration of Treatment0.07582-year-old man withR-CHOP-R,CR after 21224 WeeksStage III DLBCL,Rituximab/lenalidomidecycles(PD after 12non-GC typeBendamustine/rituximab(4 doses)doses)diagnosed in 2015Obinituzumab+gemcitabine+oxaliplatin0.6564-year old man diagnosed withdouble-hit Stage IV DLBCL inAug
69、ust 2017R-CHOP x 1 and EPOCH X 6(2017)RICE with IT prophylaxis(2017/2018)Rituximab and XRT(2018)Rituximab,gemcitabine+oxaliplatin withradiotherapy(2018)Axicabtagene ciloleucel(CAR-T)(May 2018)Rituximab and lenalidomide(Nov 2018)PR at cycle 3815 weeks(PD after 8 doses)1.2768-year old womanR-CHOPPR at
70、1027 weeksstage IV extranodalRICE x 2cycle 3ongoingDLBCL,non-GCDHAP x 2(PD at cyclediagnosed inCAR-T(May 2019)10)Feb 2018Lenalidomide(Nov 2019)1.2751-year old woman,ObinutuzumabSD639 weeksstage III marginalongoingzone lymphomadiagnosed inMay 20171.7836-year old man with stage IIIA follicularlymphoma
71、 diagnosed in June 2014Flt3L-vaccine immunotherapyRituximabPneumococcal conjugate vaccine immunotherapypolyCLC(TLR-3 agonist)immunotherapyPembrolizumabSD412 weeks (PD afterCycle 4)2.5074-year old man withIV follicular lymphomaReituximab/fludarabine/CytoxanIfosfamide/carboplatin,etoposideAuto SCTSD39
72、 weeks onactive treatment050100*Patient had a prolonged dosedelay(cycle 2 to cycle 3)due toCOVID-150Study dayIndividual patients with NHLtreatedwith STRO-001(N=18)(1)0.075 to 0.65 mg/kg Q2W0.91 mg/kg Q3W1.27 mg/kg Q3W1.78 mg/kg Q3W2.5 mg/kg Q3WContinuing study treatmentSD*PRSD SDPRCRSTRO
73、00123NON-CONFIDENTIAL$254.2Min cash,cash equivalents&marketable securities as of Sept.30,2021Projected cash runway into2H 2023(1),based on current business plans and assumptions1.6M sharesofVaxcyte(Nasdaq:PCVX)not included in the above reported cashFunding received from our collaborators of$434Mthro
74、ugh Sept.30,2021Financial OverviewWell-capitalized through cash and other financial sources24(1)Based on projections as of Sept.30,2021NON-CONFIDENTIALExperienced Leadership TeamWilliam Newell,JD Chief Executive Officer and Member of the Board of DirectorsTrevor Hallam,PhD President of Research and
75、Chief Scientific OfficerArturo Molina,MD,MS,FACPChief Medical OfficerEdAlbini,MBAChief Financial OfficerShabbirAnik,PhDChief Technical Operations OfficerLinda Fitzpatrick Chief People and Communications OfficerNicki Vasquez,PhD Chief Portfolio Strategy and Alliance OfficerNeurexLynxJane Chung,RPhChief Commercial Officer25